GO
Loading...

Teva Pharmaceutical Industries Ltd

More

  • Why rivals are jealous of Pfizer's AstraZeneca deal Thursday, 1 May 2014 | 7:15 AM ET
    U.S. drugmaker Pfizer proposed buying AstraZeneca for about 58.8 billion pounds ($98.7 billion) in what would rank as the industry's biggest-ever takeover, surpassing Pfizer's $64 billion purchase of Wyeth in 2009.

    As rivals assessed what Pfizer's play for AstraZeneca could mean for the industry, one aspect touched nearly everyone: What it could mean for a U.S. tax loophole.

  • 'Weed' portfolios, but don't sell in May: Analysts Wednesday, 30 Apr 2014 | 6:56 PM ET
    Traders work on the floor of the New York Stock Exchange on April 30, 2014.

    Stocks closed out April with a bang and many watchers believe this is not the year to sell in May.

  • Teva's abuse-resistant painkiller succeeds in study Wednesday, 30 Apr 2014 | 8:33 AM ET

    April 30- Israel's Teva Pharmaceutical Industries Ltd said its experimental abuse-resistant pain drug significantly reduced patients' chronic low back pain in a late-stage trial. The drug is a twice-daily formulation of hydrocodone, which belongs to a powerful class of painkillers known as opioids that are also frequently abused.

  • April 28- Actavis Plc said on Monday it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex. A similar lawsuit was announced Friday by Mylan Inc over generic drug marketing exclusivity for Celebrex.

  • Actavis sues FDA over generic Celebrex Monday, 28 Apr 2014 | 5:51 PM ET

    April 28- Actavis Plc on Monday said it has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Teva Pharmaceutical Industries Ltd to sell a generic version of Pfizer Inc's blockbuster painkiller Celebrex.

  • WASHINGTON, April 18- U.S. Supreme Court Chief Justice John Roberts on Friday denied a request by Teva Pharmaceutical Industries Ltd to stay a lower-court ruling in a patent case that favored the developers of generic versions of Teva's top-selling multiple sclerosis drug.

  • WASHINGTON, April 17- Teva Pharmaceutical Industries Ltd on Thursday told the U.S. Supreme Court that it is willing to post up to a $500 million bond in return for a decision suspending a lower court ruling that would allow generic competitors to go on the market as soon as next month.

  • Teva willing to post $500 million bond in Copaxone case Thursday, 17 Apr 2014 | 3:18 PM ET

    WASHINGTON, April 17- Teva Pharmaceutical Industries Ltd on Thursday told the U.S. Supreme Court that it is willing to post up to a $500 million bond in return for a decision suspending a lower court ruling that would allow generic competitors to go on the market as soon as next month.

  • April 17- Teva Pharmaceutical Industries Ltd signed a deal that allows the Israeli drugmaker to launch a generic version of Pfizer Inc's blockbuster painkiller Celebrex in December. "helps them to get through 2014 with a lot less competition," Morningstar analyst Damien Conover said.

  • Midday movers: Weibo, Sabre, Goldman Sachs & More Thursday, 17 Apr 2014 | 12:30 PM ET
    Sign for Sabre IPO on Nasdaq board

    Some of Thursday's midday movers:

  • April 17- Teva Pharmaceutical Industries Ltd said it settled a patent lawsuit with Pfizer Inc, allowing the Israeli drugmaker to launch a generic version of Pfizer's blockbuster painkiller Celebrex in December.

  • April 17- Teva Pharmaceutical Industries Ltd said it settled a patent litigation with Pfizer Inc, allowing the Israeli drugmaker to launch a generic version of Pfizer's blockbuster pain medication, Celebrex, in December. Celebrex's basic chemical patent expires on May 30.

  • Lightning Round: Delta, LinkedIn & More Tuesday, 15 Apr 2014 | 6:46 PM ET

    It's time for the Lightning Round. Cramer makes the call on viewer favorites.

  • WASHINGTON, April 14- Generic drug manufacturers on Monday asked the U.S. Supreme Court to allow a lower court ruling favoring them to take effect while the high court considers an appeal in a patent fight over Teva Pharmaceutical Industries Ltd's top-selling multiple sclerosis drug, Copaxone.

  • MUMBAI, April 9- India's Sun Pharmaceutical Industries Ltd plans to begin phasing out sales of generic drugs branded as Ranbaxy Laboratories Ltd products in the United States after completing a $3.2 billion takeover of its loss-making rival, sources with direct knowledge of the matter said.

  • Chief Justice John Roberts on Tuesday asked generic drug manufacturers to respond to a request from Teva Pharmaceutical Industries Ltd seeking to prevent a lower court ruling from taking effect while the high court considers an appeal in a patent fight over Teva's top-selling multiple sclerosis drug, Copaxone.

  • WASHINGTON, April 7- Teva Pharmaceutical Industries Ltd asked the U.S. Supreme Court on Monday to stop a lower court ruling from going into effect while the justices consider an appeal in a patent fight over Teva's top-selling multiple sclerosis drug Copaxone.

  • March 31- Eli Lilly was successful in a crucial legal battle on Monday when a U.S. The court said the defendants, Teva Pharmaceutical Industries Ltd, APP Pharmaceutical, now known as Fresenius Kabi USA LLC, Barr Laboratories Inc and Pliva Hrvatska D.O.O., failed to show by clear evidence that the asserted claims of the' 209 Patent are invalid.

  • Midday Movers: Amgen, Biogen, Priceline & More Monday, 31 Mar 2014 | 12:18 PM ET

    Take a look at some of Monday's midday movers:

  • WASHINGTON, March 31- The U.S. Supreme Court on Monday agreed to hear an appeal filed by Teva Pharmaceutical Industries Ltd in a patent fight over top-selling multiple sclerosis drug Copaxone, a move that could deter generic manufacturers from introducing cheaper versions onto the market as soon as May.